 MINNEAPOLIS--BUSINESS WIRE--DiaMedica Therapeutics Inc. Nasdaq: DMAC, a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that Dr. Harry Alcorn, its Chief Medical Officer will be presenting CKD DM199 Research Update at the 3rd Chronic Kidney Disease Drug Development CKD3 summit virtually on Tuesday March 2nd, 2021, at 1:00pm Eastern Time. The presentation will include data from the CKD Phase 1b study and an overv 